Laudisi, Federica published the artcileRepositioning of anthelmintic drugs for the treatment of cancers of the digestive system, SDS of cas: 55981-09-4, the main research area is review repositioning anthelmintic drug cancer digestive system; STAT3; Wnt/β-catenin; benzimidazole; chemotherapy; colorectal cancer; drug repurposing; hepatocellular carcinoma; niclosamide; rafoxanide; salicylanilide.
Tumors of the digestive system, when combined together, account for more new cases and deaths per yr than tumors arising in any other system of the body and their incidence continues to increase. Despite major efforts aimed at discovering and validating novel and effective drugs against these malignancies, the process of developing such drugs remains lengthy and costly, with high attrition rates. Drug repositioning (also known as drug repurposing), i.e., the process of finding new uses for approved drugs, has been gaining popularity in oncol. drug development as it provides the opportunity to expedite promising anti-cancer agents into clin. trials. Among the drugs considered for repurposing in oncol., compounds belonging to some classes of anthelmintics-a group of agents acting against infections caused by parasitic worms (helminths) that colonize the mammalian intestine-have shown pronounced anti-tumor activities and attracted particular attention due to their ability to target key oncogenic signal transduction pathways. In this review, we summarize and discuss the available exptl. and clin. evidence about the use of anthelmintic drugs for the treatment of cancers of the digestive system.
International Journal of Molecular Sciences published new progress about Anthelmintics. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, SDS of cas: 55981-09-4.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics